Imvax tackles solid tumours head-on with faster document reviews
Imvax, Inc. has a rich history of innovation when it comes to battling tumours with personalised immunotherapies. In-house experts draw on many decades of experience in biopharma development, which goes into creating therapies targeting solid tumours.
Ideagen PleaseReview was essential in supporting Imvax to achieve their objectives in 2022, overcoming the following challenges with reviewing important documentation:
- Difficulty controlling the review process
- Significant issues with version control
- Limited visibility of changes made and by whom
- Growing levels of frustration
Download the full case study to discover how Imvax have successfully accelerated their document reviews and what results they’ve achieved since implementing PleaseReview.
Ideagen PleaseReview provides a more stable and disciplined environment for document reviews. It’s a much more viable tool to use when you’re trying to get things done and stick to timelines.
